Literature DB >> 34341173

Host Defense against Klebsiella pneumoniae Pneumonia Is Augmented by Lung-Derived Mesenchymal Stem Cells.

Tirumalai Rangasamy1,2, Laxman Ghimire2, Liliang Jin2, John Le2, Sivakumar Periasamy2, Sagar Paudel2, Shanshan Cai2, Samithamby Jeyaseelan1,2,3.   

Abstract

Klebsiella pneumoniae is a common cause of Gram-negative pneumonia. The spread of antibiotic-resistant and hypervirulent strains has made treatment more challenging. This study sought to determine the immunomodulatory, antibacterial, and therapeutic potential of purified murine stem cell Ag-1+ (Sca-1+) lung mesenchymal stem cells (LMSCs) using in vitro cell culture and an in vivo mouse model of pneumonia caused by K pneumoniae. Sca-1+ LMSCs are plastic adherent, possess colony-forming capacity, express mesenchymal stem cell markers, differentiate into osteogenic and adipogenic lineages in vitro, and exhibit a high proliferative capacity. Further, these Sca-1+ LMSCs are morphologically similar to fibroblasts but differ ultrastructurally. Moreover, Sca-1+ LMSCs have the capacity to inhibit LPS-induced secretion of inflammatory cytokines by bone marrow-derived macrophages and neutrophils in vitro. Sca-1+ LMSCs inhibit the growth of K pneumoniae more potently than do neutrophils. Sca-1+ LMSCs also possess the intrinsic ability to phagocytize and kill K. pneumoniae intracellularly. Whereas the induction of autophagy promotes bacterial replication, inhibition of autophagy enhances the intracellular clearance of K. pneumoniae in Sca-1+ LMSCs during the early time of infection. Adoptive transfer of Sca-1+ LMSCs in K. pneumoniae-infected mice improved survival, reduced inflammatory cells in bronchoalveolar lavage fluid, reduced inflammatory cytokine levels and pathological lesions in the lung, and enhanced bacterial clearance in the lung and in extrapulmonary organs. To our knowledge, these results together illustrate for the first time the protective role of LMSCs in bacterial pneumonia.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34341173      PMCID: PMC8355100          DOI: 10.4049/jimmunol.2000688

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  100 in total

Review 1.  Pathways of oxidative damage.

Authors:  James A Imlay
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

2.  Th17 cells mediate clade-specific, serotype-independent mucosal immunity.

Authors:  Kong Chen; Jeremy P McAleer; Yuan Lin; David L Paterson; Mingquan Zheng; John F Alcorn; Casey T Weaver; Jay K Kolls
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

Review 3.  Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors.

Authors:  Jae W Lee; Xiaohui Fang; Anna Krasnodembskaya; James P Howard; Michael A Matthay
Journal:  Stem Cells       Date:  2011-06       Impact factor: 6.277

4.  Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome.

Authors:  Johnatas D Silva; Miquéias Lopes-Pacheco; Ana H R Paz; Fernanda F Cruz; Elga B Melo; Milena V de Oliveira; Débora G Xisto; Vera L Capelozzi; Marcelo M Morales; Paolo Pelosi; Elizabeth Cirne-Lima; Patricia R M Rocco
Journal:  Crit Care Med       Date:  2018-02       Impact factor: 7.598

5.  Characterization of mesenchymal stem cells (MSCs) from human fetal lung: potential differentiation of germ cells.

Authors:  Jinlian Hua; Haisheng Yu; Wuzi Dong; Chunrong Yang; Zhimin Gao; Anmin Lei; Yadong Sun; Shaohui Pan; Yuanyuan Wu; Zhongying Dou
Journal:  Tissue Cell       Date:  2009-08-03       Impact factor: 2.466

Review 6.  Complement receptor immunoglobulin: a control point in infection and immunity, inflammation and cancer.

Authors:  Annabelle Grace Small; Marwah Al-Baghdadi; Alex Quach; Charles Hii; Antonio Ferrante
Journal:  Swiss Med Wkly       Date:  2016-04-05       Impact factor: 2.193

7.  Primary mesenchymal stem cells in human transplanted lungs are CD90/CD105 perivascularly located tissue-resident cells.

Authors:  Sara Rolandsson; Annika Andersson Sjöland; Jan C Brune; Hongzhe Li; Moustapha Kassem; Fredrik Mertens; Albert Westergren; Leif Eriksson; Lennart Hansson; Ingrid Skog; Leif Bjermer; Stefan Scheding; Gunilla Westergren-Thorsson
Journal:  BMJ Open Respir Res       Date:  2014-05-17

8.  MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC.

Authors:  Sara Rolandsson Enes; Annika Andersson Sjöland; Ingrid Skog; Lennart Hansson; Hillevi Larsson; Katarina Le Blanc; Leif Eriksson; Leif Bjermer; Stefan Scheding; Gunilla Westergren-Thorsson
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

9.  Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Authors:  Maciej Kabat; Ivan Bobkov; Suneel Kumar; Martin Grumet
Journal:  Stem Cells Transl Med       Date:  2019-12-05       Impact factor: 6.940

10.  Phagocytic superoxide specifically damages an extracytoplasmic target to inhibit or kill Salmonella.

Authors:  Maureen Craig; James M Slauch
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.